These weight loss drugs are expensive out of pocket, though. Even with insurance, high co-pays can also limit who has access ...

For the state, the cost of funding obesity medications was too high. For the patients, the cost of losing access is higher.

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

Indianapolis-based Lilly is testing its weight loss drug Zepbound to treat addiction, while Meta outages affected more than ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...

With so many weight loss medications on the market, it's easy to feel overwhelmed by the options. From brand-name heavy ...

Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a ...

W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...